Literature DB >> 20448081

Acute lymphoid and gastrointestinal toxicity induced by selective p38alpha map kinase and map kinase-activated protein kinase-2 (MK2) inhibitors in the dog.

Dale L Morris1, Shawn P O'Neil, Rajesh V Devraj, Joseph P Portanova, Richard W Gilles, Cindy J Gross, Sandra W Curtiss, Wendy J Komocsar, Debra S Garner, Fernando A Happa, Lori J Kraus, Kristen J Nikula, Joseph B Monahan, Shaun R Selness, Gerald R Galluppi, Kimberly M Shevlin, Jeffrey A Kramer, John K Walker, Dean M Messing, David R Anderson, Robert J Mourey, Laurence O Whiteley, John S Daniels, Jerry Z Yang, Philip C Rowlands, Carl L Alden, John W Davis, John E Sagartz.   

Abstract

Exposure to moderately selective p38alpha mitogen-activated protein kinase (MAPK) inhibitors in the Beagle dog results in an acute toxicity consisting of mild clinical signs (decreased activity, diarrhea, and fever), lymphoid necrosis and depletion in the gut-associated lymphoid tissue (GALT), mesenteric lymph nodes and spleen, and linear colonic and cecal mucosal hemorrhages. Lymphocyte apoptosis and necrosis in the GALT is the earliest and most prominent histopathologic change observed, followed temporally by neutrophilic infiltration and acute inflammation of the lymph nodes and spleen and multifocal mucosal epithelial necrosis and linear hemorrhages in the colon and cecum. These effects are not observed in the mouse, rat, or cynomolgus monkey. To further characterize the acute toxicity in the dog, a series of in vivo, in vitro, and immunohistochemical studies were conducted to determine the relationship between the lymphoid and gastrointestinal (GI) toxicity and p38 MAPK inhibition. Results of these studies demonstrate a direct correlation between p38alpha MAPK inhibition and the acute lymphoid and gastrointestinal toxicity in the dog. Similar effects were observed following exposure to inhibitors of MAPK-activated protein kinase-2 (MK2), further implicating the role of p38alpha MAPK signaling pathway inhibition in these effects. Based on these findings, the authors conclude that p38alpha MAPK inhibition results in acute lymphoid and GI toxicity in the dog and is unique among the species evaluated in these studies.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20448081     DOI: 10.1177/0192623310367807

Source DB:  PubMed          Journal:  Toxicol Pathol        ISSN: 0192-6233            Impact factor:   1.902


  3 in total

1.  Anti-inflammatory effects of mapracorat, a novel selective glucocorticoid receptor agonist, is partially mediated by MAP kinase phosphatase-1 (MKP-1).

Authors:  Thomas R Vollmer; Anthony Stockhausen; Jin-Zhong Zhang
Journal:  J Biol Chem       Date:  2012-08-16       Impact factor: 5.157

2.  Blockade of MK2 is protective in inflammation-associated colorectal cancer development.

Authors:  Anita L Ray; Eliseo F Castillo; Katherine T Morris; Robert A Nofchissey; Lea L Weston; Von G Samedi; Joshua A Hanson; Matthias Gaestel; Irina V Pinchuk; Ellen J Beswick
Journal:  Int J Cancer       Date:  2015-08-21       Impact factor: 7.396

3.  Pharmacological and genetic inhibition of downstream targets of p38 MAPK in experimental nephrotic syndrome.

Authors:  Xiaojing Nie; Melinda A Chanley; Ruma Pengal; David B Thomas; Shipra Agrawal; William E Smoyer
Journal:  Am J Physiol Renal Physiol       Date:  2017-11-29
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.